These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

720 related items for PubMed ID: 9296274

  • 1. Chronic hemorheological effects of the calcium antagonist nilvadipine in essential hypertension.
    Tsuda Y, Satoh K, Kitadai M, Izumi Y, Takahashi T.
    Arzneimittelforschung; 1997 Aug; 47(8):900-4. PubMed ID: 9296274
    [Abstract] [Full Text] [Related]

  • 2. Hemorheological and hemodynamic parameters in patients with essential hypertension and their modification by alpha-1 inhibitor drug treatment.
    Toth K, Kesmarky G, Vekasi J, Nemes J, Czopf L, Kapronczay P, Halmosi R, Papp E, Juricskay I.
    Clin Hemorheol Microcirc; 1999 Aug; 21(3-4):209-16. PubMed ID: 10711745
    [Abstract] [Full Text] [Related]

  • 3. Effects of antihypertensive therapy on hemorheological profiles in female hypertensive patients with initially low or high whole blood viscosity.
    Muravyov AV, Meiselman HJ, Yakusevich VV, Zamishlayev AV.
    Clin Hemorheol Microcirc; 2002 Aug; 26(2):125-35. PubMed ID: 12082261
    [Abstract] [Full Text] [Related]

  • 4. Effects of doxazosin on hemorheological, hemodynamic and lipid parameters in patients with essential hypertension.
    Toth K, Nemes J, Czopf L, Kapronczay P, Kesmarky G, Juricskay I.
    Clin Hemorheol Microcirc; 1999 Aug; 20(1):57-61. PubMed ID: 11185685
    [Abstract] [Full Text] [Related]

  • 5. Haemorheological disturbances in hypertensive type 2 diabetic patients--influence of antihypertensive therapy.
    Kearney-Schwartz A, Virion JM, Stoltz JF, Drouin P, Zannad F.
    Fundam Clin Pharmacol; 2007 Aug; 21(4):387-96. PubMed ID: 17635177
    [Abstract] [Full Text] [Related]

  • 6. [Hemorheological alterations in hypertensive patients].
    Foresto P, D'Arrigo M, Filippini F, Gallo R, Barberena L, Racca L, Valverde J, Rasia RJ.
    Medicina (B Aires); 2005 Aug; 65(2):121-5. PubMed ID: 16075805
    [Abstract] [Full Text] [Related]

  • 7. Effects of Ramipril and Isradipin on hemorheological profiles in patients with arterial hypertension.
    Muravyov AV, Zaitsev LG, Muravyov AA, Yakusevich VV, Sirotkina AM.
    Clin Hemorheol Microcirc; 1998 Jul; 18(2-3):185-90. PubMed ID: 9699040
    [Abstract] [Full Text] [Related]

  • 8. 24-hour blood pressure control after single daily doses of nivaldipine in patients with essential hypertension.
    Lossnitzer K, Huber HJ, Kuchlbauer R, Quitzdorff G.
    J Cardiovasc Pharmacol; 1992 Jul; 20 Suppl 6():S35-42. PubMed ID: 1283187
    [Abstract] [Full Text] [Related]

  • 9. Time course of regression of vascular structural changes and its relation to cytosolic free calcium in hypertensives after nilvadipine treatment.
    Ueno H, Takata M, Oh-hashi S, Tomoda F, Yasumoto K, Inoue H.
    J Hum Hypertens; 1995 Sep; 9(9):735-9. PubMed ID: 8551487
    [Abstract] [Full Text] [Related]

  • 10. Impact of pancreas and kidney transplantation on determinants of blood and plasma viscosity.
    Mellinghoff AC, Reininger AJ, Wurzinger LJ, Landgraf R, Hepp KD.
    Clin Hemorheol Microcirc; 1998 Jul; 18(2-3):175-84. PubMed ID: 9699039
    [Abstract] [Full Text] [Related]

  • 11. Effect of parenteral or oral vinpocetine on the hemorheological parameters of patients with chronic cerebrovascular diseases.
    Feher G, Koltai K, Kesmarky G, Horvath B, Toth K, Komoly S, Szapary L.
    Phytomedicine; 2009 Mar; 16(2-3):111-7. PubMed ID: 19135345
    [Abstract] [Full Text] [Related]

  • 12. Hemorheological disturbances in patients with chronic cerebrovascular diseases.
    Szapary L, Horvath B, Marton Z, Alexy T, Demeter N, Szots M, Klabuzai A, Kesmarky G, Juricskay I, Gaal V, Czopf J, Toth K.
    Clin Hemorheol Microcirc; 2004 Mar; 31(1):1-9. PubMed ID: 15272148
    [Abstract] [Full Text] [Related]

  • 13. Effects of nilvadipine and amlodipine in patients with mild to moderate essential hypertension: a double blind, prospective, randomised clinical trial.
    Leonetti G, Italian Study Group on Nilvadipine in Mild to Moderate Hypertension.
    Curr Med Res Opin; 2005 Jun; 21(6):951-8. PubMed ID: 15969895
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A placebo-controlled 3-year study of a calcium blocker on visual field and ocular circulation in glaucoma with low-normal pressure.
    Koseki N, Araie M, Tomidokoro A, Nagahara M, Hasegawa T, Tamaki Y, Yamamoto S.
    Ophthalmology; 2008 Nov; 115(11):2049-57. PubMed ID: 18672290
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The tolerability of nilvadipine compared to nifedipine in patients with essential hypertension.
    Faust G.
    J Cardiovasc Pharmacol; 1992 Nov; 20 Suppl 6():S56-61. PubMed ID: 1283191
    [Abstract] [Full Text] [Related]

  • 19. Elevation of serum soluble E- and P-selectin in patients with hypertension is reversed by benidipine, a long-acting calcium channel blocker.
    Sanada H, Midorikawa S, Yatabe J, Yatabe MS, Katoh T, Baba T, Hashimoto S, Watanabe T.
    Hypertens Res; 2005 Nov; 28(11):871-8. PubMed ID: 16555575
    [Abstract] [Full Text] [Related]

  • 20. Nilvadipine: profile of a new calcium antagonist. An overview.
    Rosenthal J.
    J Cardiovasc Pharmacol; 1994 Nov; 24 Suppl 2():S92-107. PubMed ID: 7898101
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.